Oral Nicotinamide Riboside Raises NAD+ and Lowers Biomarkers of Neurodegenerative Pathology in Plasma Extracellular Vesicles Enriched for Neuronal Origin

Objective

To evaluate if NR could augment neuronal NAD+ levels and impact markers of neurodegeneration and insulin-signaling in plasma-derived human neuronal extracellular vesicles (NEVs).

Study Design

Randomized, double-blind, placebo-controlled, crossover study in 22 healthy, middle-aged, and older men and women

Dose

1000 mg

Duration

6 weeks

Key Outcomes

  • NR supplementation significantly increased NAD+ in plasma derived human neuronal extracellular vesicles (NEVs), suggesting an increase in neuronal NAD+ levels.

  • In NEVs, NR also decreased levels of Aβ42, an Alzheimer’s disease biomarker, as well as biomarkers pJNK and pERK1/2, which are involved in insulin resistance and neuroinflammatory pathways.

Clinical, Neurological HealthANAD StaffNeurological Health